Pages that link to "Q47954829"
Jump to navigation
Jump to search
The following pages link to An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma (Q47954829):
Displaying 11 items.
- Aberrantly DNA Methylated-Differentially Expressed Genes and Pathways in Hepatocellular Carcinoma (Q61809787) (← links)
- Treatment strategies for locally advanced hepatocellular carcinoma (Q64262622) (← links)
- Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial (Q88310077) (← links)
- Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers (Q89820887) (← links)
- CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity (Q90069496) (← links)
- Investigation of the Prognostic Significance of Vasculogenic Mimicry and Its Inhibition by Sorafenib in Canine Mammary Gland Tumors (Q92542081) (← links)
- SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma (Q92571307) (← links)
- Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma (Q92573164) (← links)
- IL‑17A promotes CXCR2‑dependent angiogenesis in a mouse model of liver cancer (Q92582058) (← links)
- Current options and future possibilities for the systemic treatment of hepatocellular carcinoma (Q93063612) (← links)
- Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies (Q97542924) (← links)